Body weight, body mass index, and age: predictors of menotropin dose and cycle outcome in polycystic ovarian syndrome?
Whereas the dose of hMG is significantly correlated with both BMI and BW, commencing the more obese patient on higher hMG doses is not justified in view of the cancellation of cycles from over-responsiveness in the more obese patients started on higher hMG dosage regimens. If the more obese patient is slow to respond, however, a greater degree of clinical freedom may be exercised to increase the dose. The ultimate outcome of the cycle is not related to BMI, BW, or the dose of hMG used.
McClure
N
N
Prince Henry's Institute of Medical Research, Melbourne, Victoria, Australia.
McQuinn
B
B
McDonald
J
J
Kovacs
G T
GT
Healy
D L
DL
Burger
H G
HG
D000375:Aging; D015992:Body Mass Index; D001835:Body Weight; D005260:Female; D006801:Humans; D008596:Menotropins / Q000008:administration & dosage* / Q000627:therapeutic use; D010062:Ovulation Induction; D011085:Polycystic Ovary Syndrome / Q000503:physiopathology*; D011247:Pregnancy
D008596:Menotropins